Rossari Biotech Ltd

Meeting Details

• Date and time: Monday, October 19, 2026, 04:00 PM IST
• Meeting type and mode: Group virtual earnings conference call
• Event/organiser: Rossari Biotech Limited Q2 & H1 FY27 Earnings Call
• Purpose: Discuss Q2 and H1 FY27 operational and financial performance; Q&A session
• Key participants: Promoter and Executive Chairman; Promoter and Managing Director; Group CFO

Rossari Biotech Ltd: Trading Window closed from October 01, 2026 till 48 hours after the announcement of Unaudited Financial Results of the Company for the quarter and half year ending on September 30, 2026.

Meeting Details

• Date and time: Tuesday, September 22, 2026, 02:00 PM IST onwards.
• Meeting type and mode: One-on-One and Group; location Mumbai.

Participants

• Key company participant: Company Secretary & Head - Legal.

Purpose

• Discuss financial and other information publicly available and covered in Earnings Presentation.

Additional Notes

• Earnings Presentation dated July 19, 2026 submitted to exchanges and uploaded on website.

Meeting Details

• Date and time: Sep 17, 2026, 10:00 AM IST onward.
• Meeting type and mode: One-on-One & Group; physical meeting in Mumbai.
• Location: Mumbai.

Participants

• Key company participants: management team (roles not specified).

Purpose

• Discuss financial information and public earnings presentation.

Materials

• Earnings Presentation uploaded on company website.

Non-participation in investor conference

• Rossari Biotech Ltd will not participate in Nirmal Bang's Semi-Annual Investor Conference on Aug 10, 2026.

Meeting Details

• Date: Monday, Aug 10, 2026; Time: 02:00 PM IST.
• Meeting type: One-on-One and Group; Mode: physical in Mumbai.
• Organizer: Nirmal Bang's Semi-Annual Investor Conference.

Purpose

• Discuss financial information and earnings presentation.

Materials Availability

• Earnings presentation submitted Jul 19, 2026 and uploaded on the website.

Consolidated highlights

• Consolidated revenue from operations rose 28% YoY to Rs 697.2 crore.
• Consolidated EBITDA up 19% to Rs 80.6 crore; margin 11.6%.
• PAT rose 4% to Rs 35.1 crore; EPS diluted Rs 6.3 (not annualised).

Standalone highlights

• Standalone revenue Rs 482.3 crore, up 32% YoY.
• Standalone EBITDA Rs 56.4 crore; margin 11.7%.
• Standalone PAT Rs 34.3 crore; up 31%.
• Standalone EPS Rs 6.2 (not annualised).

Key developments

• Greenfield blending facility in Thailand established via Unistar Thai, capacity 5,000 MTPA.
• Capacities across powders, granules and liquids; customised formulations for local market.
• Completed sale of Andheri office; ongoing monetisation of non-core assets.
• Kanjurmarg sale completed in prior quarter.

Outlook and strategic focus

• Management reiterates focus on disciplined execution, innovation and profitable growth.
• Healthy balance sheet and expanding global presence support growth.

Business Overview

• Rossari Biotech is a specialty chemicals manufacturer with HPPC, Textile, and AHN segments.
• Strategic focus on portfolio rationalisation and international expansion.
• Thailand blending facility established; capacity 5,000 MTPA.
• Monetisation of non-core assets progressing: Andheri office sale; Kanjurmarg sale earlier.

Key Operational Highlights

• Q1 FY27 revenue 697.2 cr; EBITDA 80.6 cr; PAT 35.1 cr.
• HPPC, TSC, AHN grew YoY by 28%, 28%, 27%.
• Consolidated revenue growth 28.2% YoY; margins around 11-14% across segments.
• Expanded international footprint with Thailand blending facility to serve SE Asia.
• Sale of Andheri office completed; progress on non-core asset monetisation.

Financial Performance

• Revenue from operations: 697.2 cr in Q1 FY27; +28.2% YoY.
• EBITDA 80.6 cr; EBITDA margin 11.6%.
• PAT 35.1 cr; PAT margin 5.0%.
• FY26 four-year trend: revenue 2,396 cr; EBITDA 286 cr; PAT 149 cr.
• Healthy balance sheet and liquidity support growth.

Capital Structure & Liquidity

• Zero-debt status since 2020-21.
• Monetisation of non-core assets improving liquidity.
• Capex: additional 50,000 MTPA EO derivatives capacity expansion.
• International expansion in DMCC, Jafza, Thailand, KSA, Singapore.

Strategic Priorities & Outlook

• Grow core HPPC, TSC, AHN via cross-sell and new applications.
• Invest in product development; strengthen R&D pipeline.
• Strengthen manufacturing footprint via brownfield capacities; evaluate KSA greenfield.
• Expand international distribution and partnerships; disciplined capital allocation.
• Thailand facility enhances SE Asia footprint; supply chain resilience.
• FY27: disciplined execution and profitable growth.

Governance & Leadership

• Appointment of Udeypaul Singh Gill as director; effective 28.04.2026.
• Independent directors on board; founders/promoters active in leadership.
• Subsidiaries expansion: DMCC, Jafza, Thailand, KSA, Singapore.

Financial results approved

• Unaudited standalone and consolidated results for quarter ended 30 June 2026 approved.
• Consolidated total income: Rs 7,003.87 million; standalone total income: Rs 4,844.63 million.
• Audit Committee reviewed; statutory auditors performed limited review.

ESOP 2019 grants and equity allotment

• Board approved grant of 4,000 ESOP 2019 options; price Rs 531 per option.
• Options vest 20% after year 1, 20% after year 2, 20% after year 3, 40% after year 4.
• During quarter, 8,250 shares allotted under ESOP 2019.
• 2,500 shares issued on exercise; issued capital rises to Rs 11,07,88,232.
• Total issued shares: 55,394,116; par value Rs 2 per share.

Intra-group restructuring: RILC transfer to Rossari Singapore

• Board approved transfer of 100% Rossari International Limited to Rossari Singapore.
• Subject to SPA and Saudi approvals; no material change in ultimate ownership.
• Proposed sale of 9,000 RILC shares to Rossari Singapore for ~Rs 24 crore; completion by 31 Mar 2027.
• RILC turnover Rs 0.22 crore; net worth Rs 22.425 crore as of 31-Mar-2026.

Regulatory disclosures and auditor remarks

• Related party transaction; sale to Rossari Singapore to be at arm's length.
• Auditor reports: consolidated and standalone results reviewed; no adverse remarks; unmodified conclusions.